Fig. 1From: Risks of stroke, its subtypes and atrial fibrillation associated with glucagon-like peptide 1 receptor agonists versus sodium-glucose cotransporter 2 inhibitors: a real-world population-based cohort study in Hong KongFlowchart of subject inclusion. The index date was defined as the first date of receiving SGLT2i or GLP-1RA. SGLT2i, sodium–glucose cotransporter-2 inhibitors; GLP-1RA, glucagon-like peptide-1 receptor agonistBack to article page